FDA grants orphan drug status to Ionis’ olezarsen for FCS treatment
The US FDA has granted orphan drug designation to Ionis Pharmaceuticals’ olezarsen for familial chylomicronemia syndrome (FCS).
The US FDA has granted orphan drug designation to Ionis Pharmaceuticals’ olezarsen for familial chylomicronemia syndrome (FCS).
What's Your Reaction?
